相关实验视频

Updated: Jun 17, 2025

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

德格林通过抑制CCL2/NFκB信号通路来抑制质母细胞瘤的进展

Yiming Qian¹, Jianhong Dong¹, Wei Zhang¹

¹School of Pharmacy, Hangzhou Normal University, Hangzhou, 311121, China; Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, Hangzhou Normal University, Hangzhou, 311121, Zhejiang, China.

Neuropharmacology

|August 11, 2024

概括

德格林是一种天然化合物,通过阻止细胞分裂和诱导细胞死亡,有效地抑制多形质母细胞瘤 (GBM) 的生长. 它还通过向CCL2 / NFκB通路来抑制瘤进展和血管生成.

科学领域:

神经瘤学神经瘤学
药理学药理学是指药理学的学科.
分子生物学分子生物学

背景情况:

多形质母细胞瘤 (GBM) 是一种具有不良预后的侵袭性脑瘤.
天然化合物德格林的抗癌特性已知,但其对抗GBM的机制尚不清楚.

研究的目的:

研究德格林对多种质母细胞瘤 (GBM) 的抑制作用和潜在机制.
探索德格林作为治疗GBM的治疗策略的潜力.

主要方法:

细胞活力测试,细胞周期分析,细胞亡测试和迁移测试是在用德格林治疗的GBM细胞上进行的.
用RNA测序 (RNA-seq) 来识别德格林治疗细胞中的分子变化.
使用正方形的GBM模型进行了西方涂抹和体内研究.

主要成果:

德格林通过诱导G2/M细胞周期停止和细胞亡,降低了GBM细胞活力.
德格林抑制了GBM细胞迁移和下调化学激素 (CCL2).
德格林使CCL2/NFκB信号通路失活,抑制瘤生长,改变瘤微环境,并在体内抑制血管生成.

结论:

德格林通过抑制细胞增殖,迁移和血管生成,表现出显著的抗GBM作用.
该机制涉及抑制CCL2 / NFκB信号通路.
德古林代表了质母细胞瘤治疗的有前途的治疗候选者.

关键词:

在CCL2/NFκB中.德格鲁林 (Deguelin) 的意思是说.质母细胞瘤多形瘤微环境是一个微环境.与瘤相关的微质/巨细胞.

更多相关视频

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells

Published on: November 28, 2015

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...